Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452003 | 0.86 | PTGES (0.53) | KDM4ELMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL5481419 | 0.85 | PTGS1 (0.54) | MAPK14KDM4ELMNAMAPTHPGD | |
| SCHEMBL5466784 | 0.85 | KDM4E (0.62) | KDM4ELMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL5444943 | 0.84 | ALDH1A1 (0.51) | MAPK14MAPTHPGDSMN1; SMN2 | |
| SCHEMBL5485404 | 0.83 | MTNR1A (0.56) | MAPK14 | |
| SCHEMBL11190335 | 0.83 | MAPK14 (0.56) | MAPK14KDM4E | |
| Bromide SCHEMBL11178448 | 0.82 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL5434841 | 0.80 | MAPK14 (0.56) | MAPK14KDM4ELMNAEGFRGSK3B | |
| SCHEMBL5449334 | 0.78 | MAPT (0.47) | MAPK14MAPTHPGDSMN1; SMN2 | |
| SCHEMBL9664403 | 0.78 | KDM4E (0.60) | KDM4ELMNAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | BEIERSDORF, AG | 2007-08-09 | — | — | US | disclosed |
| US-7223781-B2 | 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040116695-A1 | 2-Mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | PTGS2, PTGES2, DHFR | MAPK14 2955/4885KDM4E 520/4885LMNA 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.